{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?registeredInterest=false&creator.label=Biography+information+for+Baroness+Goudie", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?registeredInterest=false&creator.label=Biography+information+for+Baroness+Goudie", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?registeredInterest=false&_metadata=all&creator.label=Biography+information+for+Baroness+Goudie", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=0®isteredInterest=false&creator.label=Biography+information+for+Baroness+Goudie", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?registeredInterest=false&creator.label=Biography+information+for+Baroness+Goudie", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?registeredInterest=false&creator.label=Biography+information+for+Baroness+Goudie", "items" : [{"_about" : "http://data.parliament.uk/resources/1727962", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1727962/answer", "answerText" : {"_value" : "
Department officials have had a number of conversations with colleagues in NHS England, the National Institute for Health and Care Excellence (NICE), and the Medicines and Healthcare products Regulatory Agency to discuss the progress of key regulatory decisions and the National Health Service's preparations for the adoption of any licensed and NICE recommended treatment for Alzheimer\u2019s disease.<\/p>
The NICE is currently developing guidance for the NHS on the use of several potential new medicines for the treatment of Alzheimer\u2019s disease, as well as currently consulting on its draft guidance on the use of lecanemab. The NICE has determined that the benefits of this first new treatment are just too small to justify the significant cost to the NHS. These are very difficult decisions to make, and it is right that they are taken independently, and on the basis of the available evidence of costs and benefits. We understand how disappointing the NICE\u2019s draft guidance will be to all those affected, but we need to make sure that the finite resources of the NHS are only spent on treatments that are clinically and cost effective, to ensure patient and taxpayer benefit. The NICE\u2019s draft recommendations are now open to consultation, and the NICE will take the comments received fully into account in developing its final guidance.<\/p>
Lecanemab is the first disease modifying treatment for Alzheimer\u2019s disease with a marketing approval in Great Britain, and to ensure the health system is prepared for future advances in treatments, a dedicated NHS England team is already looking ahead to 27 other treatments which are currently in advanced clinical trials, that could potentially be approved by 2030.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/347", "label" : {"_value" : "Biography information for Baroness Merron"} } , "answeringMemberPrinted" : {"_value" : "Baroness Merron"} , "dateOfAnswer" : {"_value" : "2024-09-23", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-09-23T08:04:48.693Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-09-09", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Alzheimer's Disease: Medical Treatments"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government what discussions they have had with (1) the NHS, (2) NICE, and (3) MHRA, to ensure that NHS patients can access licensed treatments for Alzheimer's disease.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3575", "label" : {"_value" : "Biography information for Baroness Goudie"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Goudie"} ], "uin" : "HL882"} , {"_about" : "http://data.parliament.uk/resources/1726485", "AnsweringBody" : [{"_value" : "Foreign, Commonwealth and Development Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1726485/answer", "answerText" : {"_value" : "
The Government is committed to working with international partners and businesses to ensure global supply chains are free from human and labour rights abuses. The UK monitors all countries on the Developing Countries Trading Scheme (DCTS) on an ongoing basis for serious and systemic violations of human rights (including gender rights), labour rights and environmental obligations based on international conventions. The DCTS includes the power to suspend a country's preferential tariffs for such violations, however, it does not have the power to individually suspend a company's trade preferences.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4222", "label" : {"_value" : "Biography information for Lord Collins of Highbury"} } , "answeringMemberPrinted" : {"_value" : "Lord Collins of Highbury"} , "dateOfAnswer" : {"_value" : "2024-09-16", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-09-16T11:41:45.817Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "208"} , "answeringDeptShortName" : {"_value" : "Foreign, Commonwealth and Development Office"} , "answeringDeptSortName" : {"_value" : "Foreign, Commonwealth and Development Office"} , "date" : {"_value" : "2024-09-02", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Overseas Trade: Human Rights"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government what plans they have, if any, to deny preferential trading rights to companies from countries with poor human rights records.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3575", "label" : {"_value" : "Biography information for Baroness Goudie"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Goudie"} ], "uin" : "HL609"} , {"_about" : "http://data.parliament.uk/resources/1715948", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1715948/answer", "answerText" : {"_value" : "
The Early Years Foundation Stage Statutory Framework (EYFS) sets the standards that all early years providers must meet, for the learning, development, and care of children from birth to five years old. The EYFS requires that where children are provided with meals, snacks, and drinks, they must be healthy, balanced, and nutritious. The EYFS also refers to example menus and guidance, which support parents, carers, and anyone working with children, to provide healthy food options. The Department for Education has also very recently published a range of tools and advice to support childminders, nursery leaders, and pre-school practitioners to improve the food offered in early years settings on the Help for early years providers platform.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4948", "label" : {"_value" : "Biography information for Lord Markham"} } , "answeringMemberPrinted" : {"_value" : "Lord Markham"} , "dateOfAnswer" : {"_value" : "2024-05-17", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-17T11:51:56.363Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-05-07", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Obesity: Children"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government what plans they have, if any, to undertake a review into levels of childhood obesity and the role that the promotion of meals, snacks and drinks in early years settings can play in combatting this trend.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3575", "label" : {"_value" : "Biography information for Baroness Goudie"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Goudie"} ], "uin" : "HL4398"} , {"_about" : "http://data.parliament.uk/resources/1715949", "AnsweringBody" : [{"_value" : "Women and Equalities"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1715949/answer", "answerText" : {"_value" : "
In 2017, we introduced world-leading regulations requiring large employers to publish the differences in average salaries and bonuses for men and women every year. We continue to see high levels of compliance with the regulations; and the broader requirement has ensured that employers are aware of their gaps and are taking steps to close them.<\/p>
Enforcement of the reporting regulations is the responsibility of the Equality and Human Rights Commission. They have outlined the process that they follow for gender pay gap reporting here:<\/p>